CLAIMS

1. A pharmaceutical composition comprising a cell population comprising isolated CD106-positive and G-CSF-positive cardiac fibroblasts and a pharmaceutically acceptable component,

wherein the percentage (number of cells) of CD106-positive fibroblasts in the fibroblasts is 10% or more, and

wherein the percentage (number of cells) of G-CSF-positive fibroblasts in the fibroblasts is 10% or more.

2. The pharmaceutical composition according to claim 1, wherein the percentage (number of cells) of CD90-positive fibroblasts in the fibroblasts is 40% or more.

3. The pharmaceutical composition according to claim 1 or 2, wherein the percentage (number of cells) of CD106-positive and CD90-positive fibroblasts in the fibroblasts is 1.77% or more.

4. The pharmaceutical composition according to any one of claims 1-3, wherein the composition is used for improving cardiac functions.